The pS2 trefoil protein has been detected in close association with neuro-endocrine differentiation in prostate cancer and prostatic intraepithelial neoplasia. These preliminary results have suggested that pS2 is a candidate as a speci®c marker for prostate cancer tissue. To ascertain the speci®city of pS2 in prostate cancer tissue, we have used an RT-PCR method from prostate biopsies provided from human malignant and benign prostatic hyperplasia (BPH) tissue.
The pS2 trefoil protein has been detected in close association with neuro-endocrine differentiation in prostate cancer and prostatic intraepithelial neoplasia. These preliminary results have suggested that pS2 is a candidate as a speci®c marker for prostate cancer tissue. To ascertain the speci®city of pS2 in prostate cancer tissue, we have used an RT-PCR method from prostate biopsies provided from human malignant and benign prostatic hyperplasia (BPH) tissue.
Method
Prostate biopsies were obtained from transrectal biopsies from 153 patients with an abnormal DRE or a PSA more than 4 ng/ml or symptoms of BPH and a PSA more than 4 ng/ml. Total RNA was extracted from fresh frozen specimens of tissue samples. Detection of pS2 transcript compared to GADPH transcripts was done using RT-PCR.
Results
Biopsy results showed that 108 patients had prostate cancer (average Gleason score 6.39 AE 0.74) and 45 patients had BPH. PS2 RT-PCR results showed that pS2 RNA expression was negative in 83% of the BPH cases. Conversely, 92% of prostate cancer specimens were positive (Chi-square: 86.09, P`0.001). There was no correlation with tumour stage nor the Gleason score. Comparing the expression of pS2 in BPH and localized prostate cancer, we found a sensitivity of 92% and a speci®city of 82%.
Conclusion
On this large sample of prostate biopsies from patients at risk of having prostate cancer, pS2 was an interesting marker signi®cantly associated with prostate cancer. Further work on the expression of pS2 according to differentiation and hormonal status is in progress.
